| CircRNA: a novel type of biomarker for cancer |
133 |
| Candidate miRNAs in human breast cancer biomarkers: a systematic review |
26 |
| Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer |
26 |
| An overview of mammographic density and its association with breast cancer |
26 |
| Breast cancer incidence, mortality and mortality-to-incidence ratio (MIR) are associated with human development, 1990-2016: evidence from Global Burden of Disease Study 2016 |
22 |
| The incidence and risk factors of related lymphedema for breast cancer survivors post-operation: a 2-year follow-up prospective cohort study |
22 |
| MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast cancer by directly targeting RHBDD1 |
18 |
| The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC) |
16 |
| Up-regulated lncRNA AFAP1-AS1 indicates a poor prognosis and promotes carcinogenesis of breast cancer |
13 |
| Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials |
12 |
| PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation |
12 |
| Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines |
12 |
| p21(Waf1/Cip1): its paradoxical effect in the regulation of breast cancer |
10 |
| Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies |
9 |
| Ellagic acid, sulforaphane, and ursolic acid in the prevention and therapy of breast cancer: current evidence and future perspectives |
9 |
| HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer |
9 |
| Intimacy and sexuality in women with breast cancer: professional guidance needed |
9 |
| Oligometastatic breast cancer |
9 |
| OCT4 but not SOX2 expression correlates with worse prognosis in surgical patients with triple-negative breast cancer |
9 |
| MiR-1301-3p inhibits human breast cancer cell proliferation by regulating cell cycle progression and apoptosis through directly targeting ICT1 |
8 |
| The ubiquitin ligase COP1 regulates cell cycle and apoptosis by affecting p53 function in human breast cancer cell lines |
8 |
| Icariin induces apoptosis by suppressing autophagy in tamoxifen-resistant breast cancer cell line MCF-7/TAM |
7 |
| Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis |
7 |
| Meta-analysis for psychological impact of breast reconstruction in patients with breast cancer |
7 |
| Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy |
6 |
| LncRNA PlncRNA-1 overexpression inhibits the growth of breast cancer by upregulating TGF-1 and downregulating PHGDH |
6 |
| Adenoid cystic carcinoma of the breast, 20 years of experience in a single center with review of literature |
6 |
| Prognostic implication of the primary tumor location in early-stage breast cancer: focus on lower inner zone |
6 |
| Clinical development of CDK4/6 inhibitor for breast cancer |
6 |
| Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications |
6 |
| Does breast cancer growth rate really depend on tumor subtype? Measurement of tumor doubling time using serial ultrasonography between diagnosis and surgery |
6 |
| Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers |
6 |
| Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis |
6 |
| Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer |
5 |
| TERT promoter hotspot mutations in breast cancer |
5 |
| Risk factors for complications among breast cancer patients treated with post-mastectomy radiotherapy and immediate tissue-expander/permanent implant reconstruction: a retrospective cohort study |
5 |
| Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation |
5 |
| UBAP2L silencing inhibits cell proliferation and G2/M phase transition in breast cancer |
5 |
| Coexistence of regulatory B cells and regulatory T cells in tumor-infiltrating lymphocyte aggregates is a prognostic factor in patients with breast cancer |
5 |
| Axillary reverse mapping (ARM): where to go |
5 |
| Fat necrosis after breast-conserving oncoplastic surgery |
5 |
| Histogram analysis of quantitative pharmacokinetic parameters on DCE-MRI: correlations with prognostic factors and molecular subtypes in breast cancer |
5 |
| Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population |
5 |
| Preoperative breast MRI: reproducibility and significance of findings relevant to nipple-areolar complex involvement |
5 |
| A mathematical prediction model incorporating molecular subtype for risk of non-sentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients: a retrospective analysis and nomogram development |
4 |
| Breast cancer stem cells characterized by CD70 expression preferentially metastasize to the lungs |
4 |
| Applying new Magee equations for predicting the Oncotype Dx recurrence score |
4 |
| Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients |
4 |
| Investigating the therapeutic potential and mechanism of curcumin in breast cancer based on RNA sequencing and bioinformatics analysis |
4 |
| Identification of key gene modules and pathways of human breast cancer by co-expression analysis |
4 |
